Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Impact of body mass index (BMI) on the efficacy of plerixafor for hematopoietic progenitor cell (HPC) mobilization

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1

Data availability

The datasets generated and analyzed during the current study are not publicly available due to containing identifiable patient information but are available in a deidentified fashion from the corresponding author on reasonable request.

References

  1. Hopman RK, DiPersio JF. Advances in stem cell mobilization. Blood Rev. 2014;28:31–40.

    CAS  Article  Google Scholar 

  2. Mohty M, Duarte RF, Croockewit S, Hübel K, Kvalheim G, Russekk N. The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation. Leukemia. 2011;25:1–6.

    CAS  Article  Google Scholar 

  3. Giralt S, Costa L, Schriber J, Dipersio J, Maziarz R, McCarty J, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant. 2014;20:295–308.

    Article  Google Scholar 

  4. Basak GW, Wiktor-Jedrzejczak W, Apperley JF, Douglas KW, Gabriel IH, Geraldes C, et al. Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF. Bone Marrow Transplant. 2012;47:1003–5.

    CAS  Article  Google Scholar 

  5. Andhavarapu S, Roy V, Zubair A. Effect of body mass index on mobilizing efficacy of plerixafor in patients undergoing autologous stem cell collection: a retrospective study. Biol Blood Marrow Transplant. 2013;19 Suppl 1:S179.

    Article  Google Scholar 

  6. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma. J Clin Oncol. 2009;27:4767–73.

    CAS  Article  Google Scholar 

  7. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113:5720–6.

    CAS  Article  Google Scholar 

  8. World Health Organization Fact Sheet: Obesity and Overweight. http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed 26 Mar 2015.

  9. Costa LJ, Abbas J, Hogan KR, Kramer C, McDonald K, Butcher CD, et al. Growth factor plus preemptive (‘just-in-time’) plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure. Bone Marrow Transplant. 2012;47:1403–8.

    CAS  Article  Google Scholar 

  10. Duong HK, Savani BN, Copelan E, Devine S, Costa LJ, Wingard JR, et al. Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2014;20:1262–73.

    Article  Google Scholar 

  11. Ali MY, Oyama Y, Monreal J, Winter JN, Tallman MS, Williams SF, et al. Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation? Bone Marrow Transplant. 2003;31:861–4.

    CAS  Article  Google Scholar 

  12. Topcuoglu P, Soydan EA, Ekiz F, Ayyildiz E, Dalva K, Ozcan M, et al. How to calculate the quantity of CD34+ cells infused? A single center cohort study based on actual, ideal or adjusted ideal body weight. Transfus Apher Sci. 2007;36:275–80.

    Article  Google Scholar 

  13. Maclean PS, Parker AN, McQuaker IG, Clark AD, Farrell E, Douglas KW. Ideal body weight correlates better with engraftment after PBSC autograft than actual body weight, but is under-estimated in myeloma patients possibly due to disease-related height loss. Bone Marrow Transplant. 2007;40:665–9.

    CAS  Article  Google Scholar 

  14. Hicks C, Trickett A, Kwan YL, Ramanathan S. The use of adjusted ideal body weight for overweight patients undergoing HPC mobilisation for autologous transplantation. Ann Hematol. 2012;91:1795–801.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

SW acknowledges the WVCTSI support from the National Institute of General Medical Sciences grant U54GM104942.

Author information

Authors and Affiliations

Authors

Contributions

SY Data collection, data analysis, data interpretation, drafting paper, critical revisions, paper approval. RG Concept design, data collection, data interpretation, critical revisions, paper approval. MD Data interpretation, critical revisions, paper approval. KS Data interpretation, critical revisions, paper approval. SW Statistical analysis, critical revisions, paper approval. KR Data interpretation, critical revisions, paper approval. LV Data interpretation, critical revisions, paper approval. AC Concept design, data analysis, data interpretation, drafting paper, critical revisions, paper approval.

Corresponding author

Correspondence to Spencer K. Yingling.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Yingling, S.K., Gonzalez, R.M., Dillaman, M. et al. Impact of body mass index (BMI) on the efficacy of plerixafor for hematopoietic progenitor cell (HPC) mobilization. Bone Marrow Transplant (2022). https://doi.org/10.1038/s41409-022-01685-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41409-022-01685-8

Search

Quick links